Pulse Biosciences (PLSE) Reports Q3 Loss of $0.21
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Pulse Biosciences Quarterly Nano-Pulse Stimulation (NPS) Update
November 14, 2016 4:00 PM ESTInvestor conference call today at 1:30 p.m. PST / 4:30 p.m. EST
BURLINGAME, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc., (NASDAQ: PLSE), a medical technology company developing a proprietary therapeutic tissue treatment platform based on Nano-Pulse Stimulation (NPS), is hosting an investor conference call today to share information on new developments and significant advancements for its novel NPS platform in key... More
